Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Pretreatment Risk Stratification Tools for Prostate Cancer-Moving from Good to Better, Toward the Best.

Herlemann A.

Eur Urol. 2020 Feb;77(2):189-190. doi: 10.1016/j.eururo.2019.10.016. Epub 2019 Nov 3. No abstract available.

PMID:
31694773
2.

Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.

Zelic R, Garmo H, Zugna D, Stattin P, Richiardi L, Akre O, Pettersson A.

Eur Urol. 2020 Feb;77(2):180-188. doi: 10.1016/j.eururo.2019.09.027. Epub 2019 Oct 9.

PMID:
31606332
3.

Novel concepts for risk stratification in prostate cancer.

Patel KM, Gnanapragasam VJ.

J Clin Urol. 2016 Dec;9(2 Suppl):18-23. doi: 10.1177/2051415816673502. Epub 2016 Dec 1.

4.

Optimising preoperative risk stratification tools for prostate cancer using mpMRI.

Reisæter LAR, Fütterer JJ, Losnegård A, Nygård Y, Monssen J, Gravdal K, Halvorsen OJ, Akslen LA, Biermann M, Haukaas S, Rørvik J, Beisland C.

Eur Radiol. 2018 Mar;28(3):1016-1026. doi: 10.1007/s00330-017-5031-5. Epub 2017 Oct 6.

5.

Efficiency of pretreatment risk stratification systems for prostate cancer in a Japanese population treated with radical prostatectomy.

Koie T, Mitsuzuka K, Narita S, Yoneyama T, Kawamura S, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C.

Int J Urol. 2015 Jan;22(1):70-3. doi: 10.1111/iju.12597. Epub 2014 Aug 13.

6.

Percentage of positive biopsy cores: a better risk stratification model for prostate cancer?

Huang J, Vicini FA, Williams SG, Ye H, McGrath S, Ghilezan M, Krauss D, Martinez AA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1141-8. doi: 10.1016/j.ijrobp.2011.09.043. Epub 2011 Nov 16.

PMID:
22099043
7.

Risk calculators and updated tools to select and plan a repeat biopsy for prostate cancer detection.

Sorokin I, Mian BM.

Asian J Androl. 2015 Nov-Dec;17(6):864-9. doi: 10.4103/1008-682X.156859. Review.

8.

External validation of the ProCaRS nomograms and comparison of existing risk-stratification tools for localized prostate cancer.

Tiberi D, Rodrigues G, Pickles T, Morris J, Crook J, Martin AG, Cury F, Catton C, Lukka H, Warner A, Taussky D.

Can Urol Assoc J. 2017 Mar-Apr;11(3-4):94-100. doi: 10.5489/cuaj.4084.

9.

Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study.

Joniau S, Briganti A, Gontero P, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, Van Poppel H, Spahn M; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).

Eur Urol. 2015 Jan;67(1):157-164. doi: 10.1016/j.eururo.2014.01.020. Epub 2014 Jan 25.

PMID:
24486307
10.

Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.

Van Neste L, Hendriks RJ, Dijkstra S, Trooskens G, Cornel EB, Jannink SA, de Jong H, Hessels D, Smit FP, Melchers WJ, Leyten GH, de Reijke TM, Vergunst H, Kil P, Knipscheer BC, Hulsbergen-van de Kaa CA, Mulders PF, van Oort IM, Van Criekinge W, Schalken JA.

Eur Urol. 2016 Nov;70(5):740-748. doi: 10.1016/j.eururo.2016.04.012. Epub 2016 Apr 20.

PMID:
27108162
11.

Comparative analysis of three risk assessment tools in Australian patients with prostate cancer.

Tamblyn DJ, Chopra S, Yu C, Kattan MW, Pinnock C, Kopsaftis T.

BJU Int. 2011 Nov;108 Suppl 2:51-6. doi: 10.1111/j.1464-410X.2011.10687.x.

12.

Unification of favourable intermediate-, unfavourable intermediate-, and very high-risk stratification criteria for prostate cancer.

Zumsteg ZS, Zelefsky MJ, Woo KM, Spratt DE, Kollmeier MA, McBride S, Pei X, Sandler HM, Zhang Z.

BJU Int. 2017 Nov;120(5B):E87-E95. doi: 10.1111/bju.13903. Epub 2017 Jun 3.

13.
14.
15.

Improving Clinical Risk Stratification at Diagnosis in Primary Prostate Cancer: A Prognostic Modelling Study.

Gnanapragasam VJ, Lophatananon A, Wright KA, Muir KR, Gavin A, Greenberg DC.

PLoS Med. 2016 Aug 2;13(8):e1002063. doi: 10.1371/journal.pmed.1002063. eCollection 2016 Aug.

16.

Percentage of positive biopsy cores as predictor of clinical outcome in prostate cancer treated with radiotherapy.

Kestin LL, Goldstein NS, Vicini FA, Martinez AA.

J Urol. 2002 Nov;168(5):1994-9.

PMID:
12394693
17.

The prostate cancer risk stratification project: database construction and risk stratification outcome analysis.

Rodrigues G, Lukka H, Warde P, Brundage M, Souhami L, Crook J, Cury F, Catton C, Mok G, Martin AG, Vigneault E, Morris J, Warner A, Maldonado SG, Pickles T; Genitourinary Radiation Oncologists of Canada.

J Natl Compr Canc Netw. 2014 Jan;12(1):60-9.

PMID:
24453293
18.

Prediction of erectile function following treatment for prostate cancer.

Alemozaffar M, Regan MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR, Sanda MG.

JAMA. 2011 Sep 21;306(11):1205-14. doi: 10.1001/jama.2011.1333.

19.

Personalizing prostate cancer diagnosis with multivariate risk prediction tools: how should prostate MRI be incorporated?

Schoots IG, Padhani AR.

World J Urol. 2019 Aug 9. doi: 10.1007/s00345-019-02899-0. [Epub ahead of print]

PMID:
31399825
20.

Pre-treatment risk stratification of prostate cancer patients: A critical review.

Rodrigues G, Warde P, Pickles T, Crook J, Brundage M, Souhami L, Lukka H; Genitourinary Radiation Oncologists of Canada.

Can Urol Assoc J. 2012 Apr;6(2):121-7. doi: 10.5489/cuaj.11085.

Supplemental Content

Support Center